β-blockade abolishes the augmented cardiac tPA release induced by transactivation of heterodimerised bradykinin receptor-2 and β2-adrenergic receptor in vivo

Thromb Haemost. 2014 Nov;112(5):951-9. doi: 10.1160/TH14-01-0059. Epub 2014 Jul 31.

Abstract

Bradykinin (BK) receptor-2 (B2R) and β2-adrenergic receptor (β2AR) have been shown to form heterodimers in vitro. However, in vivo proofs of the functional effects of B2R-β2AR heterodimerisation are missing. Both BK and adrenergic stimulation are known inducers of tPA release. Our goal was to demonstrate the existence of B2R-β2AR heterodimerisation in myocardium and to define its functional effect on cardiac release of tPA in vivo. We further investigated the effects of a non-selective β-blocker on this receptor interplay. To investigate functional effects of B2R-β2AR heterodimerisation (i. e. BK transactivation of β2AR) in vivo, we induced serial electrical stimulation of cardiac sympathetic nerves (SS) in normal pigs that underwent concomitant BK infusion. Both SS and BK alone induced increases in cardiac tPA release. Importantly, despite B2R desensitisation, simultaneous BK infusion and SS (BK+SS) was characterised by 2.3 ± 0.3-fold enhanced tPA release compared to SS alone. When β-blockade (propranolol) was introduced prior to BK+SS, tPA release was inhibited. A persistent B2R-β2AR heterodimer was confirmed in BK-stimulated and non-stimulated left ventricular myocardium by immunoprecipitation studies and under non-reducing gel conditions. All together, these results strongly suggest BK transactivation of β2AR leading to enhanced β2AR-mediated release of tPA. Importantly, non-selective β-blockade inhibits both SS-induced release of tPA and the functional effects of B2R-β2AR heterodimerisation in vivo, which may have important clinical implications.

Keywords: Tissue plasminogen activator; beta-2-adrenergic receptor; beta-blocker; bradykinin receptor-2; receptor heterodimerisation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-2 Receptor Antagonists / pharmacology*
  • Animals
  • Bradykinin / pharmacology
  • Dimerization
  • Female
  • Heart Ventricles / drug effects
  • Heart Ventricles / metabolism*
  • Immunoprecipitation
  • Male
  • Models, Cardiovascular
  • Myocardium / metabolism
  • Norepinephrine / metabolism
  • Propranolol / pharmacology
  • Receptor, Bradykinin B2 / chemistry
  • Receptor, Bradykinin B2 / physiology*
  • Receptors, Adrenergic, beta-2 / chemistry
  • Receptors, Adrenergic, beta-2 / physiology*
  • Sus scrofa
  • Swine
  • Tissue Plasminogen Activator / metabolism*
  • Transcriptional Activation

Substances

  • Adrenergic beta-2 Receptor Antagonists
  • Receptor, Bradykinin B2
  • Receptors, Adrenergic, beta-2
  • Propranolol
  • Tissue Plasminogen Activator
  • Bradykinin
  • Norepinephrine